9.095  0.005 (0.06%)		06-23 15:58
Open: 9.1 High: 9.1 Volume: 5,558,437		Pre. Close: 9.09 Low: 9.09 Market Cap: 1,199(M)

Short term
Mid term
Targets	6-month :	10.62	1-year :	12.41
Resists	First :	9.1	Second :	10.62
Pivot price	9.06
Supports	First :	8.98	Second :	8.92
MAs	MA(5) :	9.08	MA(20) :	9.06
	MA(100) :	6.15	MA(250) :	0
MACD	MACD :	0.3	Signal :	0.5
%K %D	K(14,3) :	92.8	D(3) :	94.4
RSI	RSI(14): 83.7
52-week	High :	9.1	Low :	4

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ CTIC ] has closed below upper band by 15.8%. Bollinger Bands are 95.1% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 16 bars. This is a sign that the market may be about to initiate a new trend.

If tomorrow:	Open lower	Open higher
High:	9.11 - 9.15	9.15 - 9.19
Low:	8.98 - 9.03	9.03 - 9.08
Close:	9.01 - 9.09	9.09 - 9.17

CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States. It offers VONJO (pacritinib), an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R for the treatment of adult patients with myelofibrosis. It has license and collaboration agreement with Teva Pharmaceutical Industries Ltd.; S*BIO Pte Ltd.; and Baxalta. The company was formerly known as Cell Therapeutics, Inc. and changed its name to CTI BioPharma Corp. in May 2014. CTI BioPharma Corp. was incorporated in 1991 and is headquartered in Seattle, Washington.

Sat, 20 Apr 2024
CTI BioPharma: 3Q Earnings Snapshot - AOL

Sat, 01 Jul 2023
Top Stocks for July 2023 - Investopedia

Tue, 30 May 2023
CTI BioPharma Announces Cancellation of its 2023 Annual Meeting of Stockholders - Yahoo Finance

Tue, 16 May 2023
CTI BioPharma: $1.7bn M&A With 85% Premium, Expect The Deal To Go Through (CTIC) - Seeking Alpha

Wed, 10 May 2023
European Swedish Orphan Biovitrum To Acquire CTI BioPharma For $1.7B - Yahoo Finance

Wed, 10 May 2023
CTI BioPharma Stock Soars on Deal to Be Acquired for $1.7 Billion - Barron's

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Outperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Outperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	132 (M)
Shares Float	100 (M)
Held by Insiders	5.5 (%)
Held by Institutions	83.2 (%)
Shares Short	11,270 (K)
Shares Short P.Month	12,170 (K)

EPS	-0.55
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	-0.19
Profit Margin	-91.4 %
Operating Margin	-73.6 %
Return on Assets (ttm)	-28.6 %
Return on Equity (ttm)	0 %
Qtrly Rev. Growth	950.7 %
Gross Profit (p.s.)	0.38
Sales Per Share	0.57
EBITDA (p.s.)	-0.41
Qtrly Earnings Growth	0 %
Operating Cash Flow	-82 (M)
Levered Free Cash Flow	-85 (M)

PE Ratio	-16.85
PEG Ratio	0
Price to Book value	-47.87
Price to Sales	15.83
Price to Cash Flow	-14.58

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.